Argyriou AA - Search Results

1

Papapetropoulos S, Argyriou AA. Papapetropoulos S, et al. Among authors: argyriou aa. Acta Neurol Scand. 2008 Apr;117(4):224-30. doi: 10.1111/j.1600-0404.2007.00936.x. Epub 2007 Oct 10. Acta Neurol Scand. 2008. PMID: 17927802 Review.

2

Clinical characteristics of late-onset Parkinson disease.

Papapetropoulos S, Argyriou AA, Ellul J. Papapetropoulos S, et al. Among authors: argyriou aa. Arch Neurol. 2003 Dec;60(12):1815-6; reply 1816. doi: 10.1001/archneur.60.12.1815. Arch Neurol. 2003. PMID: 14676067 No abstract available.

3

Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease.

Papapetropoulos S, Argyriou AA, Ellul J, Chroni E. Papapetropoulos S, et al. Among authors: argyriou aa. Eur J Neurol. 2004 Feb;11(2):115-9. doi: 10.1046/j.1351-5101.2003.00727.x. Eur J Neurol. 2004. PMID: 14748772

4

Psychosocial effects and evaluation of the health-related quality of life in patients suffering from well-controlled epilepsy.

Argyriou AA, Papapetropoulos S, Polychronopoulos P, Corcondilas M, Argyriou K, Heras P. Argyriou AA, et al. Among authors: argyriou k. J Neurol. 2004 Mar;251(3):310-3. doi: 10.1007/s00415-004-0313-7. J Neurol. 2004. PMID: 15015011

5

The effect of vascular disease on late onset Parkinson's disease.

Papapetropoulos S, Ellul J, Argyriou AA, Talelli P, Chroni E, Papapetropoulos T. Papapetropoulos S, et al. Among authors: argyriou aa. Eur J Neurol. 2004 Apr;11(4):231-5. doi: 10.1046/j.1468-1331.2003.00748.x. Eur J Neurol. 2004. PMID: 15061824

6

A case of L-dopa-responsive parkinsonian syndrome after low-dose oral methotrexate intake.

Papapetropoulos S, Argyriou AA, Liossis SN, Daousis D, Katsoulas G, Apostolopoulos D, Chroni E. Papapetropoulos S, et al. Among authors: argyriou aa. Clin Neuropharmacol. 2004 Mar-Apr;27(2):95-8. doi: 10.1097/00002826-200403000-00011. Clin Neuropharmacol. 2004. PMID: 15252273 No abstract available.

7

Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.

Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, Iconomou G, Kalofonos HP. Argyriou AA, et al. Neurology. 2005 Jan 11;64(1):26-31. doi: 10.1212/01.WNL.0000148609.35718.7D. Neurology. 2005. PMID: 15642899 Clinical Trial.

8

Clinical and epidemiological features of motor neuron disease in south-western Greece.

Argyriou AA, Polychronopoulos P, Papapetropoulos S, Ellul J, Andriopoulos I, Katsoulas G, Salakou S, Chroni E. Argyriou AA, et al. Acta Neurol Scand. 2005 Feb;111(2):108-13. doi: 10.1111/j.1600-0404.2004.00362.x. Acta Neurol Scand. 2005. PMID: 15644070

9

Factors associated with drug-induced visual hallucinations in Parkinson's disease.

Papapetropoulos S, Argyriou AA, Ellul J. Papapetropoulos S, et al. Among authors: argyriou aa. J Neurol. 2005 Oct;252(10):1223-8. doi: 10.1007/s00415-005-0840-x. Epub 2005 Apr 18. J Neurol. 2005. PMID: 15834642

10

The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients.

Heras P, Argyriou AA, Papapetropoulos S, Karagiannis S, Argyriou K, Mitsibounas D. Heras P, et al. Among authors: argyriou k, argyriou aa. Eur J Cancer Care (Engl). 2005 May;14(2):108-12. doi: 10.1111/j.1365-2354.2005.00571.x. Eur J Cancer Care (Engl). 2005. PMID: 15842457

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

185 results

Search Page